Literature DB >> 11738930

Population pharmacokinetics of gabapentin in infants and children.

D Ouellet1, H N Bockbrader, D L Wesche, D Y Shapiro, E Garofalo.   

Abstract

PURPOSE: To characterize gabapentin pharmacokinetics in infants and children using a population approach and to identify important demographic and/or physiologic determinants of gabapentin disposition.
METHODS: Gabapentin was administered in single doses of 10 mg/kg (N=48 healthy subjects, age 1 month-12 years) or in multiple doses of 10-65 mg/kg per day (N=205 patients with epilepsy, age 2 months-13 years) at 08:00, 14:00, and 20:00. Serial concentration-time data from the healthy subjects were combined with sparse data obtained in patients and were modeled using NONMEM.
RESULTS: Gabapentin oral clearance (l/h) was directly related to creatinine clearance (ml/min) with a slope of 0.116. The slope of the relationship was 36% greater in blacks than in subjects of other races. When oral clearance was normalized for body weight, young children (<5 years) had higher and more variable values than older children. Volume of distribution was related to body weight and appeared to differ between subjects and patients. Intersubject variability was approximately 30% for oral clearance and volume of distribution and was larger for the absorption rate constant and lag time. Residual variability, a measure of intrasubject variability and measurement error, was smaller in subjects than in patients.
CONCLUSIONS: On a weight basis, 33% larger doses would be required in younger children (<5 years) to achieve the same exposure as older children.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738930     DOI: 10.1016/s0920-1211(01)00311-4

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  13 in total

1.  Gabapentin Use for Hospitalized Neonates.

Authors:  Hibo H Abdi; Nathalie L Maitre; Kristen L Benninger; Mark E Hester; Jonathan L Slaughter
Journal:  Pediatr Neurol       Date:  2019-02-21       Impact factor: 3.372

Review 2.  Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Authors:  Svein I Johannessen; Torbjörn Tomson
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Clinical development of antiepileptic drugs for children.

Authors:  Elizabeth Garofalo
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

4.  Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil.

Authors:  Chao Chen
Journal:  Eur J Clin Pharmacol       Date:  2013-06-07       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

Authors:  Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Developmental pharmacokinetics in pediatric populations.

Authors:  Hong Lu; Sara Rosenbaum
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

Review 7.  Use of second-generation antiepileptic drugs in the pediatric population.

Authors:  Allison M Chung; Lea S Eiland
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

8.  Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1.

Authors:  Phuong Tran; Hee-Doo Yoo; Lien Ngo; Hea-Young Cho; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-10-10       Impact factor: 2.745

9.  Dosing Recommendations for Pediatric Patients With Renal Impairment.

Authors:  Amer Al-Khouja; Kyunghun Park; Daijha J C Anderson; Caitlyn Young; Jian Wang; Shiew Mei Huang; Mona Khurana; Gilbert J Burckart
Journal:  J Clin Pharmacol       Date:  2020-06-15       Impact factor: 3.126

10.  A novel computational biostatistics approach implies impaired dephosphorylation of growth factor receptors as associated with severity of autism.

Authors:  K M Wittkowski; V Sonakya; B Bigio; M K Tonn; F Shic; M Ascano; C Nasca; G Gold-Von Simson
Journal:  Transl Psychiatry       Date:  2014-01-28       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.